Welcome to Peptide Card of AntiTbPdb
This page displays user query in tabular form. |
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES details |
Primary information | |
---|---|
ID | antitb_1389, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacteria smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | MIC = 1μg /ml |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | J774.A1 macrophage cell lines |
In vivo Model | 14% bacteria is cleared |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1390, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacteria smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | MIC = 1μg /ml (after 6 hours) |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | J774.A1 macrophage cell lines |
In vivo Model | 34% bacteria is cleared |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1391, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacteria smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | MIC = 25μg/ml |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | J774.A1 macrophage cell lines |
In vivo Model | 41% bacteria is cleared |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1392, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacteria smegmatis |
In Vitro/ In vivo | M. smegmatis mc2 155 |
Cell Line | MIC = 25μg /ml (after 6 hours incubation) |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | J774.A1 macrophage cell lines |
In vivo Model | 67% bacteria is cleared |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1399, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacteria bovis |
In Vitro/ In vivo | Mycobacteria bovis BCG |
Cell Line | MIC = 25μg/ml |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | THP-1 cells |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1400, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacteria bovis |
In Vitro/ In vivo | Mycobacteria bovis BCG |
Cell Line | MIC = 25μg /ml (after 624hours incubation) |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | THP-1 cells |
In vivo Model | > 60% bacteria is cleared |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1403, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC = 25μg/ml (24 hours incubation) |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1404, |
Name | 21790937 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 38 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Murine macrophages |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC = 100 μg/mL (72 hours incubation) |
Inhibition Concentration | in vitro |
Sequence | 2011 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1528, |
Name | 25613372 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 37 |
Source | L |
Origin | Cationic |
Species | Protein derived |
Strain | Derived from Human cationic antimicrobial protein 18 (hCAP18) |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | MIC = 2.1 μg/ml |
Inhibition Concentration | in vitro |
Sequence | 2015 |
Cytotoxicity | Human macrophage THP1 |
In vivo Model | NA |
Lethal Dose | No cytotoxicity |
Immune Responce | C57BL/6 Mice |
Mechanism of Action | NA |
Target | Induce expression of IL-8 and MCP-1 |
Combination Therapy | In vitro binding of bacterilamembrane and induce pore formation while in vivo activate TLR and monocyte to kill bacteria |
Other activities | Bacterial cell membrane |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1628, |
Name | 26218806 |
N-Terminal modification | LL-37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 37 |
Source | L |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium smegmatis |
In Vitro/ In vivo | Mycobacteria smegmatis mc2 155 |
Cell Line | MIC = 2400 μg/ml |
Inhibition Concentration | in vitro |
Sequence | 2015 |
Cytotoxicity | J774 macrophage cell lines |
In vivo Model | NA |
Lethal Dose | IC50= 11226 μg/ml |
Immune Responce | NA |
Mechanism of Action | NA |
Target | Stimulation of TNF-α production |
Combination Therapy | inhibit bacterial Atpase activity |
Other activities | NA |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information | |
---|---|
ID | antitb_1811, |
Name | 23141114 |
N-Terminal modification | LL- 37 |
C-Terminal Modification | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 37 |
Source | L |
Origin | Cationic |
Species | Natural |
Strain | Human cells |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis strain H37Rv |
Cell Line | MIC = 5 μM |
Inhibition Concentration | Both |
Sequence | 2012 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | Male BALB/c mice |
Mechanism of Action | a significant reduction in bacilli loads |
Target | NA |
Combination Therapy | Disruption of cell wall and membrane |
Other activities | cell wall and membrane |
PMID | NA |
Year of Publication | Antibacterial (P.aeruginosa) |
Tertiary Structure (Technique) | Not Predicted), |